Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.39 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL778326 | 0.98 | TAAR1 (0.46) | TAAR1HTR2AKCNH2FFAR1CA12 | |
| Methane SCHEMBL7260125 | 0.96 | TAAR1 (0.45) | TAAR1HTR2AKCNH2FFAR1CA12 | |
| SCHEMBL3136280 | 0.86 | MGLL (0.44) | TAAR1HTR2AKCNH2FFAR1 | |
| SCHEMBL3139486 | 0.84 | MGLL (0.51) | TAAR1FFAR1CA2 | |
| SCHEMBL2441516 | 0.80 | TAAR1 (0.50) | TAAR1HTR2AKCNH2CA12CA1 | |
| SCHEMBL4704224 | 0.79 | TAAR1 (0.45) | TAAR1CA12CA1CA2CA4 | |
| SCHEMBL2377547 | 0.79 | TAAR1 (0.45) | TAAR1HTR2ACA12CA1CA2 | |
| SCHEMBL28822705 | 0.78 | CA2 (0.52) | FFAR1CA12CA1CA2CA9 | |
| SCHEMBL27711383 | 0.78 | CA2 (0.52) | FFAR1CA12CA1CA2CA9 | |
| SCHEMBL8145771 | 0.78 | ESR1 (0.56) | TAAR1CA1CA2HTR2CPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1191026-B1 | New pyridazine endothelin antagonists | PFIZER LTD (GB) | 2004-05-19 | — | — | EP | disclosed |
| US-6670362-B2 | Treatment of restenosis, acute or chronic renal failure, pulmonary hypertension, systemic hypertension, benign prostatic hyperplasia, male erectile dysfunction, prostate cancer, metastatic bone cancer, angina, atherosclerosis | PFIZER INC. | 2003-12-30 | — | — | US | disclosed |
| US-20020061889-A1 | New pyridazine endothelin antagonists | PFIZER INC. | 2002-05-23 | — | — | US | disclosed |
| EP-1191026-A1 | New pyridazine endothelin antagonists | Pfizer Limited (GB) | 2002-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061889-A1 | New pyridazine endothelin antagonists | EDNRB, EDNRA, ECE1 | TAAR1 61/4885HTR2A 65/4885KCNH2 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.